SKSvetlana V. Khokhlova

Svetlana V. Khokhlova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Svetlana V. Khokhlova has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Resolution on the results of the expert council on the topic “Expanding options for maintenance therapy of ovarian cancer: the place of the new PARP inhibitor Fuzuloparib in Russian clinical guidelines”

    by S. V. Khokhlova, A. A. Rumyantsev, I. A. Pokataev, D. A. Nosov, S. V. Averyanova, A. S. Danilova, R. A. Zukov, D. A. Istomin, L. A. Kolomiets, M. A. Krasilnikova, et al.

    Expert advisory board meetings were held on April 2, 2026, and July 3, 2026, during which the country’s leading oncologists discussed the current state of pharmacological therapy for ovarian cancer and the prospects for introducing a new selective PARP inhibitor, fuzuloparib. The treatment of malignant ovarian neoplasms remains one of the most challenging areas in gynecologic oncology. Although ovarian cancer ranks third in incidence—following endometrial and cervical cancers—it firmly holds the top spot in terms of mortality. Approximately 14,000 new cases are diagnosed annually in Russia, with over 40% of patients diagnosed at advanced stages (III–IV). The advent of PARP inhibitors has fundamentally transformed the maintenance therapy paradigm for BRCA-associated and HRD-positive cancers; however, the availability of this class of drugs in the Russian Federation remains limited, and current practice necessitates an expansion of therapeutic options.

  • Open Access

    Current approaches to first-line therapy for endometrial cancer: the role of lenvatinib and pembrolizumab combination therapy

    by V. M. Nechushkina, S. V. Khokhlova, D. A. Nosov, E. A. Ulrikh, L. A. Kolomiets, A. A. Rumyantsev, G. A. Raskin

    Endometrial cancer (EC) remains the most common gynecologic oncology disease in Russia, with a tendency toward increasing incidence and associated mortality. In recent years, significant progress has been made in understanding the molecular mechanisms underlying the disease, leading to the development of a molecular classification of EC, which has enabled the implementation of personalized treatment approaches. Determining the status of microsatellite instability (MSI) and deficiency in the mismatch repair system (dMMR), as well as identifying mutations in the POLE and TP53 genes, has become a key component in diagnosis and decision-making regarding therapy.The combination of lenvatinib and pembrolizumab has demonstrated clinical efficacy in pMMR / MSS EC in the second-line setting. The Study 309 and LEAP-001 trials confirm the clinical benefit of lenvatinib and pembrolizumab in patients with pMMR / MSS tumor phenotypes following prior systemic therapy. Expert consensus highlights the necessity of testing all patients for dMMR / MSI at initial EC diagnostics and supports the early use of immunotargeted therapy with lenvatinib and pembrolizumab already in the setting for patients with pMMR / MSS phenotype and prior adjuvant systemic therapy. The aim of this review is to analyze current approaches to systemic therapy for EC, assess the clinical significance of lenvatinib and pembrolizumab therapy, and examine the role of molecular diagnostics in guiding treatment decisions.

  • Open Access

    Benefits and limitations of breastfeeding for mothers with malignant tumors

    by Olga B. Ladodo, Mariia V. Iurova, Svetlana V. Khokhlova, Valerii V. Rodionov, Elena L. Sheshko, Viktor V. Zubkov, Mziya I. Makieva, Dar’iA A. Chutkova, Elena S. Akhapkina, Dmitriy N. Degtyarev, et al.

    In the modern world breastfeeding (BF) is considered as a significant factor in reducing the risk of developing malignant tumors of the mammary gland and ovaries. However, the problem of maintenance or refusing BF in malignant neoplasms (malignant neoplasms) still remains open. In recent years, there has been a steady increase in breast cancer (BC), especially in developed countries, with more than 10% of all breast malignancies (BC) diagnosed in women under 40 years of age. The presented article highlights aspects of maintaining lactation in different periods of the relevance of BF in relation to the timing of manifestation of cancer, and also presents data from the multicenter study POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer) on the possibilities of implementing reproductive function and BF in women receiving therapy for hormone-receptor positive (HR+) BC stages I–III. BF with cancer detected in the postpartum period depends on the treatment of the underlying disease. In patients undergoing surgical treatment, BF is not contraindicated, but it is not always technically possible. During chemotherapy, BF is not recommended. When carrying out radiotherapy, it is possible to undergo BF using a healthy mammary gland. There is currently no evidence to suggest that BF woman diagnosed with cancer may have any negative effects. In general, it has been shown that preserving and maintaining lactation in women with a history of cancer is safe for both mother and child.


  • Open Access

    Features of feeding newborns in mothers with the oncological diseases during a chemotherapy during pregnancy

    by E.S. Akhapkina, M.I. Makieva, S.V. Khokhlova, E.S. Polushkina, S.I. Zhdanova, Kazan State Medical University of the Ministry of Health of the Russian Federation, V.V. Zubkov

    Особенности вскармливания новорожденных у матерей с онкологическими заболеваниями и химиотерапией во время беременности

  • Open Access

    Health status of children born from mothers with breast cancer during pregnancy: a review of the literature

    by E.S. Akhapkina, M.I. Makieva, S.V. Khokhlova, V.V. Zubkov, O.B. Ladodo

    Особенности состояния здоровья детей, рожденных у матерей с раком молочной железы во время беременности: обзор литературы


  • Open Access

    Possibilities of Drug Correction of Menopausal Syndrome in Reproductive Cancer Patients

    by O.V. Shabalova, S.V. Yureneva, Zh.R. Gardanova, E.I. Ermakova, S.V. Khokhlova, Russian Federation Moscow

    Данная статья "Возможности медикаментозной коррекции климактерического синдрома у больных онкологическими заболеваниями органов репродуктивной системы" представлена автором "О.В. Шабалова, С.В. Юренева, Ж.Р. Гарданова, Е.И. Ермакова, С.В. Хохлова" из раздела "Гинекология". Анонс «Доктор.Ру» Том 22, № 5 (2023) .


  • Open Access

    Association of polymorphic markers of the XRCC1, ERCC5, TP53, CDKN1A1 genes with the survival of patients after platinum-based chemotherapy for triple negative breast cancer

    by T. M. Zavarykina, P. K. Lomskova, M. A. Kapralova, O. O. Gordeeva, I. P. Ganshina, D. S. Khodyrev, S. V. Khokhlova, I. V. Kolyadina

    Background. Breast cancer is the most common cancer among women. Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, in which there are no special targets for therapy. Therefore chemotherapy is still leading treatment for TNBC including the regiments with platinum drugs.Aim. To study the association of polymorphic markers of the genes XRCC1 (rs25487), ERCC5 (rs17655), TP53 (rs1042522), CDKN1A1 (rs1801270) with progression-free survival (PFS) and overall survival (OS) of TNBC patients after platinum-based neoadjuvant chemotherapy.Materials and methods. Polymorphic markers of the XRCC1, ERCC5, CDKN1A and TP53 genes were studied in blood samples of 67 patients with stage II–III TNBC by real-time polymerase chain reaction with fluorescent allele-specific probes. The results of determining the markers were compared with PFS and OS using the Kaplan–Meyer method and the log-rank-test.Results. The association was found for the polymorphic marker rs25487 of the XRCC1 gene with PFS (carrying the T/T genotype was associated with a decrease of median PFS: 15.6 months versus 34.3 months, p = 0.013) and OS (carrying the T allele was associated with a decrease of median OS: 24.3 months versus 34.6 months, p = 0.041) without depending on the BRCA status. For the polymorphic marker rs17655 of the ERCC5 gene, significant difference in PFS was obtained in the period from 15.4 to 60.0 months of follow-up (the carrier of the C allele was associated with a decrease of median PFS: 20.0 months versus 35.2 months, p = 0.035). When considering the genotypes of the polymorphic marker of the ERCC5 gene differences were revealed between patients with the C/C genotype (M = 15.9 months) and two other genotypes (M = 33.6 months), p = 0.039. For the polymorphic marker rs1801270 of the CDKN1A gene significant differences in PFS were obtained in the period from 15.4 to 60.0 months of follow-up (for carriers of allele A, a decrease in median PFS was observed: 16.6 months versus 32.0 months, p = 0.046). For the polymorphic marker of the TP53 gene (rs1042522) a tendency to decrease OS for carriers of the C/C genotype was found seems promising for further study.Conclusion. The association of the studied polymorphic markers of the genes XRCC1 (rs25487), ERCC5 (rs17655) and CDKN1A (rs1801270) with PFS was revealed in patients with TNBC. Association with OS was obtained for the polymorphic marker of the XRCC1 gene (rs25487). These data may allow for further validation to individualize the treatment of this category of patients.

  • Numerical Simulation of the Galaxies Outer Spiral Structure: The Influence of the Dark Halo Non-Axisymmetry on the Gaseous Disk Shape

    by Volgograd State University, Maria Butenko, Iraida Belikova, Nikolay Kuzmin, Svetlana Khokhlova, Gennadiy Ivanchenko, Anastasiya Ten, Igor Kudina

    A detailed analysis of the results of numerical simulation of the outer spiral structure in a gaseous galactic disk caused by the presence of non-axisymmetry in the distribution of matter in a dark halo have been fulfilled. The result obtained in our previous work [8] that the non-axisymmetry of the gaseous disk is less than the non-axisymmetry in the dark mass distribution for disks with a spiral structure extending far beyond the optical radius, have been confirmed. Also, the result has been generalized for the dark halo model, which is spherical within the optical radius and non-axisymmetric beyond it.


  • Role of Microribonucleic acid in the Carcinogenesis of Non-Small-Cell Lung Cancer

    by Marina S. Gubenko, Vitaliy I. Loginov, Aleksey M. Burdennyy, Irina V. Pronina, Svetlana V. Khokhlova, Sergey S. Pertsov, Перцов Сергей Сергеевич

    INTRODUCTION: Lung cancer is the most common malignant neoplasm. Despite advances in target therapy, immunotherapy, and chemotherapy, non-small cell lung cancer remains the major cause of cancer-related death worldwide. Tumor development is a complex process that depends on the influence of environmental factors and genetic predisposition. Although oncogenic factors have received much attention, the main mechanisms for oncogenesis are still poorly understood. Thus, studying the oncogenic mechanisms, including those with the involvement of microribonucleic acid (microRNA), is important for the diagnostics and treatment of malignant neoplasms. MicroRNA (miRNA) belong to the class of small non-coding ribonucleic acids that are involved in various cellular biological processes, including epithelialmesenchymal transition, apoptosis, proliferation, invasion, and metastatic dissemination of cancer cells. Recent publications show that the course of the oncological disease can be predicted by evaluating the expressions of some miRNAs. Therefore, miRNAs serve as promising diagnostic and therapeutic targets in oncological diseases. CONCLUSION: This review summarizes data on the role in carcinogenesis and prognostic significance of several miRNA (i.e., miRNA-128, -4500, -222, -224, -124, -125b, -127, -129-2, -137, and -375) in non-small cell lung cancer.